Novartis is once again looking to be a pioneer in cell and gene therapy, though this time is selecting a potentially less complex administration method.

Scrip takes an infographic look at where South Korea stands in the development of a wide-ranging set of drugs for Alzheimer’s disease and which companies are still in the challenging race.

Rutger Zietsma, founder of Manus Neurodynamica and one of In Vivo's Rising Leaders of 2022, explains how his prior work guided his journey into executorship, and the issues of trust and talent in a start-up environment. 

Plus deals involving Shionogi/NEC, Ji Xing/LENZ, Kyowa Kirin/Ardelyx, CR Pharma/Everest Medicine and Dr Reddy’s/Novartis.